Background HIV patients are at a higher risk of hepatitis B virus (HBV) infection than general population. The aim of this study is to assess the immunogenicity of inactivated hepatitis B vaccine among HIV infected patients.
Methods A total of 536 HIV infected patients from a university hospital in Barcelona who were vaccinated against HBV between 1996 and 2009 were analysed. Anti-HBs titles were evaluated after the last hepatitis B dose for each patient. Multivariate logistic regression was conducted to identify independent factors (sex, age, hepatitis C coinfection, HIV viral load, CD4 count, type of schedule, dose and number of vaccines) associated with vaccine response.
Results About 71% of the vaccinated HIV population were respondents (Anti-HBs antibodies ≥10 IU/l). Vaccine recipients receiving <3 doses (OR 0.29, 95% CI 0.16 to 0.52) and performing an accelerated schedule (0, 7, 21 days and booster dose at month 6) (OR 2.10, 95% CI 1.02 to 3.22) were factors associated with a decreased likelihood of a positive response. Development of anti-HBs was higher in patients with CD4 count ≥350 cells/μl (OR 1.78, 95% CI 1.37 to 2.94), HIV-RNA <50 copies/ml (OR 2.13, 95% CI 1.41 to 3.22) and 40 μg dose schedule (OR 1.82, 95% CI 1.14 to 2.94).
Conclusions These findings show that a 40 μg dose schedule and earlier vaccination from HIV diagnose may be effective strategies for an increased HBV response among HIV infected patients. Anti-HBs titles should be assessed after an accelerated vaccination schedule and after any schedule in patients who present a viral load <50 copies/ml or CD4 count <350 cells/μl, given the low likelihood of response.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.